Get started
Avadel Pharmaceuticals plcAvadel Pharmaceuticals plcAvadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

AVDL chart


Full chart

AVDL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪784.63 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.52 USD
Net income (FY)
‪−48.83 M‬ USD
Revenue (FY)
‪169.12 M‬ USD
Shares float
‪88.27 M‬
Beta (1Y)
0.75

Employees


Employees (FY)
188
Change (1Y)
+34 +22.08%
Revenue / Employee (1Y)
‪899.56 K‬ USD
Net income / Employee (1Y)
‪−259.74 K‬ USD

About Avadel Pharmaceuticals plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Gregory J. Divis
Website
avadel.com
Headquarters
Dublin
Founded
2015
ISIN
IE00BDGMC594
FIGI
BBG00FPFX9W4
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AVDL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AVDL highest yielding bonds


A
AVDL5570622
Avadel Finance Cayman Ltd. 6.0% 01-APR-2027
Yield to maturity
−5.18%
Maturity date
Apr 1, 2027

See all AVDL bonds 


Check out other big names from the same industry as AVDL.

Frequently Asked Questions


The current price of AVDL is 8.01 USD — it has decreased by −2.22% in the past 24 hours. Watch Avadel Pharmaceuticals plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avadel Pharmaceuticals plc stocks are traded under the ticker AVDL.
AVDL stock has fallen by −7.46% compared to the previous week, the month change is a −2.10% fall, over the last year Avadel Pharmaceuticals plc has showed a −52.26% decrease.
We've gathered analysts' opinions on Avadel Pharmaceuticals plc future price: according to them, AVDL price has a max estimate of 22.00 USD and a min estimate of 13.00 USD. Watch AVDL chart and read a more detailed Avadel Pharmaceuticals plc stock forecast: see what analysts think of Avadel Pharmaceuticals plc and suggest that you do with its stocks.
AVDL reached its all-time high on Sep 19, 2003 with the price of 43.60 USD, and its all-time low was 0.71 USD and was reached on Sep 21, 2001. View more price dynamics on AVDL chart.
See other stocks reaching their highest and lowest prices.
AVDL stock is 5.26% volatile and has beta coefficient of 0.75. Track Avadel Pharmaceuticals plc stock price on the chart and check out the list of the most volatile stocks — is Avadel Pharmaceuticals plc there?
Today Avadel Pharmaceuticals plc has the market capitalization of ‪784.63 M‬, it has increased by 10.50% over the last week.
Yes, you can track Avadel Pharmaceuticals plc financials in yearly and quarterly reports right on TradingView.
Avadel Pharmaceuticals plc is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
AVDL earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.03 USD resulting in a −43.00% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Avadel Pharmaceuticals plc earnings.
Avadel Pharmaceuticals plc revenue for the last quarter amounts to ‪50.41 M‬ USD, despite the estimated figure of ‪50.00 M‬ USD. In the next quarter, revenue is expected to reach ‪50.49 M‬ USD.
AVDL net income for the last quarter is ‪−5.04 M‬ USD, while the quarter before that showed ‪−2.63 M‬ USD of net income which accounts for −92.11% change. Track more Avadel Pharmaceuticals plc financial stats to get the full picture.
No, AVDL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 28, 2025, the company has 188 employees. See our rating of the largest employees — is Avadel Pharmaceuticals plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Avadel Pharmaceuticals plc EBITDA is ‪−39.72 M‬ USD, and current EBITDA margin is −23.49%. See more stats in Avadel Pharmaceuticals plc financial statements.
Like other stocks, AVDL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avadel Pharmaceuticals plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avadel Pharmaceuticals plc technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avadel Pharmaceuticals plc stock shows the sell signal. See more of Avadel Pharmaceuticals plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.